Literature DB >> 31292109

New drugs: where did we go wrong and what can we do better?

Beate Wieseler1, Natalie McGauran2, Thomas Kaiser2.   

Abstract

Mesh：

Year:  2019        PMID： 31292109     DOI： 10.1136/bmj.l4340

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  15 in total

1.  The Porto European Cancer Research Summit 2021.

Authors:  Ulrik Ringborg; Anton Berns; Julio E Celis; Manuel Heitor; Josep Tabernero; Joachim Schüz; Michael Baumann; Rui Henrique; Matti Aapro; Partha Basu; Regina Beets-Tan; Benjamin Besse; Fátima Cardoso; Fátima Carneiro; Guy van den Eede; Alexander Eggermont; Stefan Fröhling; Susan Galbraith; Elena Garralda; Douglas Hanahan; Thomas Hofmarcher; Bengt Jönsson; Olli Kallioniemi; Miklós Kásler; Eva Kondorosi; Jan Korbel; Denis Lacombe; José Carlos Machado; José M Martin-Moreno; Francoise Meunier; Péter Nagy; Paolo Nuciforo; Simon Oberst; Júlio Oliveiera; Maria Papatriantafyllou; Walter Ricciardi; Alexander Roediger; Bettina Ryll; Richard Schilsky; Grazia Scocca; Raquel Seruca; Marta Soares; Karen Steindorf; Vincenzo Valentini; Emile Voest; Elisabete Weiderpass; Nils Wilking; Amanda Wren; Laurence Zitvogel
Journal:  Mol Oncol       Date:  2021-09-13       Impact factor: 6.603

Review 2.  Reversal and Remission of T2DM - An Update for Practitioners.

Authors:  Lina Shibib; Mo Al-Qaisi; Ahmed Ahmed; Alexander D Miras; David Nott; Marc Pelling; Stephen E Greenwald; Nicola Guess
Journal:  Vasc Health Risk Manag       Date:  2022-06-14

3.  Continual proteomic divergence of HepG2 cells as a consequence of long-term spheroid culture.

Authors:  Andrea Antonio Ellero; Iman van den Bout; Maré Vlok; Allan Duncan Cromarty; Tracey Hurrell
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

4.  EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations.

Authors:  Kim Boesen; Peter C Gøtzsche; John P A Ioannidis
Journal:  Epidemiol Psychiatr Sci       Date:  2021-04-30       Impact factor: 6.892

5.  Impact of physicians' participation in non-interventional post-marketing studies on their prescription habits: A retrospective 2-armed cohort study in Germany.

Authors:  Cora Koch; Jörn Schleeff; Franka Techen; Daniel Wollschläger; Gisela Schott; Ralf Kölbel; Klaus Lieb
Journal:  PLoS Med       Date:  2020-06-26       Impact factor: 11.069

6.  The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.

Authors:  Catherine Schuster Bruce; Petra Brhlikova; Joseph Heath; Patricia McGettigan
Journal:  PLoS Med       Date:  2019-09-10       Impact factor: 11.069

7.  Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making.

Authors:  Robbe Saesen; Stéphane Lejeune; Gianluca Quaglio; Denis Lacombe; Isabelle Huys
Journal:  Front Pharmacol       Date:  2020-02-05       Impact factor: 5.810

8.  Leading Causes of Mortality and Prescription Drug Coverage in Canada and New Zealand.

Authors:  Nigel S B Rawson
Journal:  Front Public Health       Date:  2020-10-30

9.  Comparing direct acting antivirals for hepatitis C using observational data - Why and how?

Authors:  Jim Young; Stanley Wong; Naveed Z Janjua; Marina B Klein
Journal:  Pharmacol Res Perspect       Date:  2020-10

Review 10.  Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer.

Authors:  Stefanie Broes; Robbe Saesen; Denis Lacombe; Isabelle Huys
Journal:  Clin Transl Sci       Date:  2020-08-29       Impact factor: 4.689
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.